Analyst Price Target is $71.71
▲ +20.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Dr. Reddy's Laboratories in the last 3 months. The average price target is $71.71, with a high forecast of $80.00 and a low forecast of $63.41. The average price target represents a 20.11% upside from the last price of $59.70.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Dr. Reddy's Laboratories. This Buy consensus rating has held steady for over two years.
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.